.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Novartis
Chubb
Medtronic
Teva
Boehringer Ingelheim
Federal Trade Commission
Dow
Cantor Fitzgerald
AstraZeneca

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,231,095

« Back to Dashboard

Summary for Patent: 5,231,095

Title: S-timolol hemihydrate
Abstract:A novel compound and compositions containing S-(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5 thiadiazole hemihydrate useful for administration to a patient particularly for topical administration as a pharmaceutical agent for treating known conditions and disorders treatable with timolol.
Inventor(s): Peralampi; Markku (Kangasala, FI)
Assignee: Leiras Oy (Turku, FI)
Application Number:07/663,853
Patent Claim Types:
see list of patent claims
Compound; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,231,095

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Finland884838Oct 20, 1988
PCT Information
PCT FiledOctober 13, 1989PCT Application Number:PCT/FI89/00196
PCT Publication Date:May 03, 1990PCT Publication Number: WO90/04592

International Patent Family for Patent: 5,231,095

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2139781► Subscribe
Czech Republic9500044► Subscribe
Czech Republic282168► Subscribe
Germany68918597► Subscribe
Germany69220484► Subscribe
Denmark72591► Subscribe
Denmark175377► Subscribe
Denmark0577913► Subscribe
Estonia03078► Subscribe
European Patent Office0440684► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Fish and Richardson
Chinese Patent Office
Colorcon
Merck
Daiichi Sankyo
AstraZeneca
Healthtrust
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot